Screening, Testing, or Personalized Medicine: Where do Inherited Thrombophilias Fit Best?

被引:4
|
作者
Walker, Peggy [2 ]
Gregg, Anthony R. [1 ,2 ]
机构
[1] Univ S Carolina, Sch Med, Div Maternal Fetal Med, Dept Obstet & Gynecol, Columbia, SC 29203 USA
[2] Univ S Carolina, Sch Med, Div Clin Genet & Mol Med, Dept Obstet & Ginecol, Columbia, SC 29203 USA
关键词
Thrombophilia; Genetic screening; Pregnancy; Adverse pregnancy outcomes; Factor V Leiden; Prothrombin G20210A; FACTOR-V-LEIDEN; INTRAUTERINE FETAL-DEATH; VENOUS THROMBOEMBOLISM; PROTHROMBIN GENE; PROTEIN-S; METHYLENETETRAHYDROFOLATE REDUCTASE; ANTITHROMBIN DEFICIENCY; PREGNANCY OUTCOMES; HIGH PREVALENCE; APC RESISTANCE;
D O I
10.1016/j.ogc.2010.02.018
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Inherited thrombophilias present an opportunity to review population-based screening paradigms. Inherited thrombophilias are a group of complex conditions, and women who carry mutations in implicated genes have an increased risk of adverse pregnancy outcomes as well as venous thromboembolism. That asymptomatic carriers are at risk of manifesting phenotypes moves these conditions out of the traditional molecular genetic "screening" paradigm. Like most complex disorders, residual risk remains after molecular testing for thrombophilia, and the magnitude of this risk has not been quantified. Family and personal history are important factors to consider when providing personal risk assessment to patients. Overall, "testing" for thrombophilias according to a personalized medicine model is more appropriate than population "screening" as performed in other mendelian genetic conditions.
引用
收藏
页码:87 / +
页数:22
相关论文
共 15 条
  • [1] WHERE DO OCCUPATIONAL-MEDICINE RESIDENCIES FIT IN THE INSTITUTION
    MCCUNNEY, RJ
    COUTURIER, A
    JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE, 1993, 35 (09) : 889 - 890
  • [2] Considerations in Testing for Inherited Breast Cancer Predisposition in the Era of Personalized Medicine
    Powers, Benjamin
    Pal, Tuya
    Laronga, Christine
    SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2018, 27 (01) : 1 - +
  • [3] PHARMACOGENOMICS OF ADME AND PERSONALIZED MEDICINE WHERE DO WE STAND?
    Schwab, Matthias
    DRUG METABOLISM AND PHARMACOKINETICS, 2017, 32 (01) : S15 - S15
  • [4] The route to personalized medicine in bladder cancer: where do we stand?
    Massari, Francesco
    Ciccarese, Chiara
    Santoni, Matteo
    Brunelli, Matteo
    Conti, Alessandro
    Modena, Alessandra
    Montironi, Rodolfo
    Santini, Daniele
    Cheng, Liang
    Martignoni, Guido
    Cascinu, Stefano
    Tortora, Giampaolo
    TARGETED ONCOLOGY, 2015, 10 (03) : 325 - 336
  • [5] The route to personalized medicine in bladder cancer: where do we stand?
    Francesco Massari
    Chiara Ciccarese
    Matteo Santoni
    Matteo Brunelli
    Alessandro Conti
    Alessandra Modena
    Rodolfo Montironi
    Daniele Santini
    Liang Cheng
    Guido Martignoni
    Stefano Cascinu
    Giampaolo Tortora
    Targeted Oncology, 2015, 10 : 325 - 336
  • [6] Where does stool DNA testing FIT in the CRC screening menu?
    Lisa Hutchinson
    Nature Reviews Clinical Oncology, 2014, 11 (5) : 239 - 239
  • [7] FROM GENOMICS TO PATHOBIOLOGY AND PERSONALIZED MEDICINE - WHERE DO WE STAND IN PSYCHIATRY
    Gallinat, J.
    EUROPEAN PSYCHIATRY, 2012, 27
  • [8] Where Do Anxious Children "Fit" Best? Childcare and the Emergence of Anxiety in Early Childhood
    Coplan, Robert
    Findlay, Leanne C.
    Schneider, Barry H.
    CANADIAN JOURNAL OF BEHAVIOURAL SCIENCE-REVUE CANADIENNE DES SCIENCES DU COMPORTEMENT, 2010, 42 (03): : 185 - 193
  • [9] Where does it FIT? The roles of fecal testing and colonoscopy in colorectal cancer screening
    Hillyer, Grace Clarke
    Neugut, Alfred I.
    CANCER, 2015, 121 (18) : 3186 - 3189
  • [10] Expending Colorectal Cancer Screening or Promoting Personalized Medicine? One Size Does Not Fit All!
    Braillon, Alain
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (07): : 1174 - 1174